SCHEMBL2183270

SCHEMBL2183270

CC(=O)Oc1ccc(C(F)(F)F)cc1Br

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 3/20 0.60
KDM4E B2RXH2 2/20 0.60
ALDH1A1 P00352 2/20 0.60
USP2 O75604 1/20 0.60
HPGD P15428 1/20 0.60
HSD17B10 Q99714 1/20 0.60
BACE1 P56817 1/20 0.52
CYP1A2 P05177 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2D6 P10635 1/20 0.44
ATM Q13315 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
CFD P00746 2/20 0.44
CYP1A1 P04798 2/20 0.42
CYP1B1 Q16678 2/20 0.42
TSHR P16473 2/20 0.41
GAA P10253 1/20 0.41
RAB9A P51151 1/20 0.41
CYP4F2 P78329 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19438437 0.84 CYP2C19 (0.46) CYP2C19KDM4EALDH1A1USP2HPGD
SCHEMBL5176013 0.84 CYP2C19 (0.47) CYP2C19KDM4EALDH1A1USP2HPGD
SCHEMBL27781530 0.82 KDM4E (0.77) CYP2C19KDM4EALDH1A1USP2HPGD
SCHEMBL1714974 0.81 KDM4E (0.62) CYP2C19KDM4EALDH1A1USP2HPGD
SCHEMBL4981997 0.81 KDM4E (0.62) CYP2C19KDM4EALDH1A1USP2HPGD
SCHEMBL24436827 0.81 KDM4E (0.62) CYP2C19KDM4EALDH1A1USP2HPGD
SCHEMBL5769694 0.80 KDM4E (0.60) CYP2C19KDM4EALDH1A1USP2HPGD
SCHEMBL1743420 0.79 KDM4E (0.59) CYP2C19KDM4EALDH1A1USP2HPGD
SCHEMBL4976918 0.78 CYP2C19 (0.67) CYP2C19KDM4EALDH1A1USP2HPGD
SCHEMBL24436828 0.78 CYP2C19 (0.67) CYP2C19KDM4EALDH1A1USP2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110166132-A1 Gamma Secretase Modulators AMGEN INC. (US) 2011-07-07 US disclosed
EP-2231602-A1 GAMMA SECRETASE MODULATORS Amgen, Inc (US) 2010-09-29 EP disclosed
WO-2009075874-A1 GAMMA SECRETASE MODULATORS AMGEN INC. (US) 2009-06-18 WO disclosed
EP-1784388-A1 BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE AstraZeneca AB (SE) 2007-05-16 EP disclosed
WO-2006021759-A1 BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE ASTRAZENECA AB (SE) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166132-A1 Gamma Secretase Modulators BACE1, BACE2, PSEN1 CYP2C19 4369/4885KDM4E 2860/4885ALDH1A1 3262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.